Associated Genetic Biomarkers
CD274 Amplification is present in 0.32% of AACR GENIE cases, with breast carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, melanoma, and sarcoma having the greatest prevalence .
CD274 Amplification serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain CD274 Amplification as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Trials with CD274 Amplification in the inclusion eligibility criteria most commonly target gastric carcinoma and malignant solid tumor .
Atezolizumab, durvalumab, paclitaxel, and tremelimumab are the most frequent therapies in trials with CD274 Amplification as an inclusion criteria .
Significance of CD274 Amplification in Diseases
Malignant Solid Tumor +
CD274 is mutated in 2.35% of malignant solid tumor patients with CD274 Amplification present in 0.88% of all malignant solid tumor patients .
CD274 Amplification is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CD274 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
Atezolizumab is the most frequent therapy in trials for malignant solid tumor that contain CD274 Amplification .
Gastric Carcinoma +
CD274 is mutated in 0.28% of gastric carcinoma patients with CD274 Amplification present in 0.28% of all gastric carcinoma patients .
CD274 Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 Amplification and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Durvalumab, paclitaxel, and tremelimumab are the most frequent therapies in trials for gastric carcinoma that contain CD274 Amplification .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.